Pelacarsen
- Generic Name
- Pelacarsen
- Drug Type
- Biotech
- CAS Number
- 1637637-70-7
- Unique Ingredient Identifier
- LSO9H7UZ90
- Background
Pelacarsen is under investigation in clinical trial NCT03070782 (Phase 2 Study of ISIS 681257 (Akcea-apo(a)-lrx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease).
Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients
- First Posted Date
- 2018-04-24
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT03506854
- Locations
- 🇨🇦
Clinical Site, Québec, Canada
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
Phase 1
Completed
- Conditions
- Elevated Lipoprotein(a)Cardiovascular Diseases
- Interventions
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT03426033
- Locations
- 🇨🇦
Clinical Site, Mount Royal, Quebec, Canada
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel
Phase 1
Completed
- Conditions
- Elevated Lipoprotein(a)Cardiovascular Diseases
- Interventions
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT03392051
- Locations
- 🇨🇦
Clinical Site, Mount Royal, Quebec, Canada
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
Phase 2
Completed
- Conditions
- Elevated Lipoprotein(a)Cardiovascular Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Akcea Therapeutics
- Target Recruit Count
- 286
- Registration Number
- NCT03070782
- Locations
- 🇳🇱
Clinical Site, Amsterdam, Netherlands
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)
Phase 1
Completed
- Conditions
- Elevated Lipoprotein(a)
- Interventions
- Drug: Sterile Normal Saline (0.9% NaCl)
- First Posted Date
- 2015-04-13
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02414594
- Locations
- 🇨🇦
Clinical Site, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath